The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery study: A surgical perspective gold standard for left main (LM) and three vessel coronary artery 
INTRODUCTION
The treatment of symptomatic coronary artery disease has undergone major developmental changes in the last few decades.
Coronary artery bypass surgery has become a safe procedure with in-hospital mortality that averages 1% in low risk patients and between 2-5% in all risk patient groups. New innovations like less invasive techniques (mini-bypass, off-pump surgery), arterial revascularisation, optimal cardio-protective measures, major advances in anaesthetic technique and improved perioperative care has improved outcomes after coronary bypass surgery. (9, 15, 16) Since the inception of PCI in 1977 by Gruentzig, the treatment of stenotic coronary artery disease has changed forever. The introduction of bare metal stents (BMS), then drug-eluting stents (DES) and new anti-platelet therapy has been the stimulus to treat more complex coronary artery lesions with percutaneous techniques.
Several studies of multi-vessel coronary disease have shown relative comparative mortality rates in both treatment groups, with only higher repeat revascularisation rates in the PCI groups. When refl ecting on these results the question arises if CABG is still the with three vessel disease and/or LMD. The SYNTAX Study is the most important comparative evidence-based study to determine the best treatment option for LM and three vessel disease.
CURRENT EVIDENCE FOR TREATMENT IN

MULTI-VESSEL CORONARY ARTERY DISEASE
Multiple randomised control trials comparing PCI and CABG in the last ± 20 years have failed to address the issue of LM and three vessel disease. Fifteen RCT including RITA, ERACI I, GABI, EAST, CABRI, MASS I, BARI, AWESOME, MASS II, ARTS I and SOS trials gave inconclusive results regarding this aspect. (1) (2) (3) (4) (5) (6) (7) (8) In summary all of these studies included only 35% of three vessel disease, 0% had LM disease, only 43% had proximal LAD (left anterior descending artery) disease, 100% had ejection fractions of >50%, diabetes was only present in 16%. The studies exclude the bulk of patients that would benefi t from CABG (Table 1 ).
In the studies where BMS (bare metal stenting) was used, namely ERACI II, ARTS I, SOS and AWESOME the rate of repeat revascularisation was reduced signifi cantly, but was still high. In the SOS and ARTS I trial (67% -72% 2VD; 0% LM) the repeat revascularisation was 30% (BMS) vs 9% (CABG) in the ARTS I trial and 21% (BMS) vs 6% (CABG) in the SOS trial. The combined MACCE (death, MI, stroke, repeat revascularisation) was 41.7% in the BMS group and 21.8% in the CABG group. In the 5 year follow-up in the MASS II trial comparing CABG, PCI (BMS) and medical treatment groups, there was a 10 time higher incidence of repeat interventions in the PCI group in comparison with the CABG group (32.2% vs 3.5%). There was also a mild mortality difference over the 5 years favouring CABG (15.5% (PCI) VS 12.8% (CABG)). These studies tended to give a biased view with only a low percentage (4%) of screened patients being randomised. The trials excluded patients that would benefi t from bypass surgery i.e. those with three vessel disease, left main disease, patients with diabetes mellitus and those with impaired left ventricle function (<50%). Although these studies were not representative of daily clinical practice, the results were generalised. (19) A search for "real world" evidence in registries developed from these highly selective patient trials. Hannan et al. published the 3 year outcome of coronary artery bypass grafting vs stent In the CABG group 0.3% underwent re-CABG and 4.6% underwent PCI in the 3 year time period. In the PCI group 7.8% underwent CABG and 27.3% underwent repeated PCI. The observed rate of revascularisation in the CABG group was signifi cantly lower (p<0,001).
When comparing the PCI and CABG group there was a survival benefi t for CABG over the 3 years. There was a signifi cant survival benefi t in the group of patients who had three vessel disease and involvement of the proximal LAD (89.3% vs 84.4% survival when comparing CABG vs PCI over these 3 years). (9) This was an observational study and not a randomised control study and was therefore criticised by Flaherty. He concluded that there are major fl aws in the study and he emphasised that there was a risk-ascertainment bias between the two groups and therefore the difference in adjusted outcome in this study. (17) Very few of these patients received drug-eluting stents (DES). The study population included 9 963 DES patients and 7 437
CABG patients. The outcomes up to 18 months after the initial procedure were reviewed.
It was a purely observational, non-randomised, retrospective study of a "real world" situation. The revascularisation rate in the CABG group was low with 0,1% of patients requiring repeat CABG and 5.1% in the PCI group receiving repeat procedures. In the DES group 2.2% required CABG and 28.4% required repeat PCI.
In the three vessel and two vessel disease subgroup there was an The study design A non-inferiority comparison of the 2 groups was performed for the primary endpoints -a major cardiac or cerebrovascular event (death from any cause, stroke, myocardial infarction or repeat revascularisation). Patients who did not qualify were entered into a separate parallel CABG or PCI registry.
All the angiograms were reviewed by an independent group of specialists in Rotterdam, Netherlands. A SYNTAX Score was calculated for these angiograms.
SYNTAX Score
The SYNTAX Score is an anatomical assessment score of an individual angiogram (Figure 1 ). It is an evaluation of coronary lesion complexity and a score is assigned to it. It includes multiple factors, eg. lesion calcifi cation, bi-or trifurcation lesions, left main or threevessel disease, thrombus, tortuosity, number and location of lesions.
Scores are computer generated (www.syntaxscore.com).
A score of ≤22: Low Syntax Score The primary clinical endpoint is the 1 and 2 year follow-up of major adverse cardiac and cerebral events (MACCE). The 24 month follow-up has just been completed. MACCE is defi ned as the all-cause death, myocardial infarction, any repeat revascularisation and cerebrovascular events. The study is ongoing and the study will terminate when 5 year follow-up has been completed.
A non-inferiority comparison between the two therapeutic entities was done. A zone of non-inferiority was specifi ed between the differences of the MACCE rate of CABG vs PCI. The pre-specifi ed value was 6.6%. A value of less than 6.6% would suggest noninferiority for PCI compared to CABG.
Randomised cohort of the SYNTAX Study
Demographics between the CABG and TAXUS groups were nearly similar. Twenty eight % of patients were diabetic and the Euroscore and Parsonnet scores were 3.8 and 8.4 respectively in both groups.
SYNTAX Score in the CABG group was 29.1 and 28.4 in the TAXUS group. Subgroups of left main (LM) disease and three vessel disease were identical in both groups (65% and 34%).
In the TAXUS group a mean of 3.6 lesions was treated and 4.6 stents was implanted/patient. Total length of stents implanted was 86.1 ± 47.9 mm and in 33.2% of patients stenting of >100 mm was performed.
In the CABG group 15% of patients were off-pump cases, 97.3%
received at least one arterial graft, 95.6% received an arterial graft to LAD, 27.6% received double arterial grafts (RIMA/LIMA). Only 2.6% of patients received only venous grafts (Table 2) .
Primary endpoint for 12 month MACCE (The non-inferiority analysis):
Difference in MACCE = 8.3%, therefore the non-inferiority comparison was not met for the primary outcome at 12 months. (11) Subgroup MACCE rate:
Non-inferiority was not proven in this randomised cohort, therefore information for each subgroup is of an observational nature and is hypothesis generating. At 24 months the MACCE rate in the three vessel disease subgroup was 23.8% in the PCI group and 14.4% in the CABG group (p<0.001). In the left main subgroup the MACCE rate was 22.9%
in the PCI group and 19.3% in the CABG group (p=0.27). 
RESULTS IN THE PCI AND CABG REGISTRIES
One hundred and ninety-eight (198) patients were enrolled in the PCI registry and 1 077 in the CABG registry. The CABG group had a higher SYNTAX Score than the PCI group and was therefore ineligible for PCI. The PCI group had a higher Euroscore, because of more co-morbidities (Table 3) . (12) 
DISCUSSION
The SYNTAX Study is a landmark study in the treatment of three vessel and left mainstem coronary artery disease. The allcomer design will make it possible to evaluate the proper treatment option for any given clinical situation. However it should be noted that 1 077 (35%) of all the patients screened (n = 3 075) were not eligible for PCI. One hundred and ninety-eight (6.4%) patients
were not suitable for CABG, due to a high logistic Euroscore.
The higher MACCE for PCI in the randomised control cohort and registry was due to higher repeat procedures as well as higher myocardial infarction rates. There was also a high incidence of staged procedures in the PCI group (14.1% in TAXUS RCT and 13.0% PCI registry). The economic implications will be signifi cant. The peri-procedure rate of myocardial infarction after CABG is SYNTAX STUDY 3-6%. In patients with angiographic defi ned post-procedure graft closure and acute myocardial infarction the mortality is 9.3% if treated with PCI and 39% if treated with re-CABG. (18) A signifi cant difference in mortality and repeat procedure in especially the three vessel disease/LM+two vessel disease/ LM+three vessel disease groups favouring CABG. The reason for this increase in cardiac-related deaths in the PCI group is most probably due to the fact that CABG led to more complete revascularisation compared to PCI. This is more pronounced in the registry co-hort (CABG=2.5%, TAXUS=7.3%).
An increased cerebrovascular event rate in the CABG group of 1.6%. That amounts to a 3 times higher CVA rate in the CABG group. The CVA rate during the second 12 months shows an equivocal increase in both goups.
The SYNTAX score will be an important scoring system to decide on the best treatment option. In the CABG group the MACCE rate in all the SYNTAX Score levels was similar. Collaboration between surgeon and interventional cardiologist will be important in the future to optimise the best treatment option.
Complexity of coronary artery anatomy, the patient's risk for a specifi c procedure (Euroscore, Parsonnet) and the economic implications should be considered before embarking on a specifi c procedure. (14) The 5 year follow-up will be completed in 2011 and will give us much-needed information about the ideal therapy for a specifi c coronary artery profi le.
The treatment of complex coronary artery disease should ideally be managed by a team approach. The SYNTAX Study emphasises the benefi ts of surgery in this patient population at two year follow up. CABG is known to have good long term results and we need to determine if the same results can be achieved by stenting.
At present CABG remains the preferred treatment for complex
